AlloHCT Outcomes From ECOG ACRIN E1910 in Newly Diagnosed, MRD-Negative B-Lineage ALL
George Yaghmour, MD, and Rachel Elizabeth Rau, MD, on alloHCT outcomes from the ECOG ACRIN E1910 trial of blinatumomab.
Related Articles
Dato-DXd Plus Durvalumab ± Carboplatin Delivers Antitumor Activity in Advanced NSCLC
Frontline treatment with datopotamab deruxtecan plus durvalumab with/without carboplatin proved active in advanced NSCLC without actionable alterations.
Against the Wind
You do your best to protect your skin from the sun. But did you know Mother Nature ups the ante on windy days? Our experts…
China’s NMPA Accepts MAA for Foritinib in ALK+ Advanced NSCLC
China’s NMPA has accepted an MAA seeking the approval of foritinib for ALK-positive advanced non–small cell lung cancer.
Neratinib Generates CNS Responses Across HER2+ Breast Cancer Brain Metastases Subgroups
Neratinib-containing combinations are consistently effective across CNS end points in patients with HER2-positive breast cancer brain metastases.
EC Approves Nivolumab/Ipilimumab in Frontline Unresectable HCC
The CheckMate 9DW trial found that nivolumab and ipilimumab elicited a median OS of 23.7 months compared with 20.6 months from lenvatinib or sorafenib.
How Ohio State cancer experts are working to prevent lymphoma in Ethiopia
Ohio State cancer doctors are taking their expertise to Ethiopia to help prevent lymphoma through a program focused on treatment, vaccination and education.
China’s NMPA Approves Sacituzumab Tirumotecan for Pretreated EGFR+ Advanced NSCLC
The Chinese NMPA has approved sacituzumab tirumotecan for EGFR-mutant advanced NSCLC following progression on an EGFR TKI and chemotherapy.
Defeating lethal cancer: Interrupting the ecologic and evolutionary basis of death from malignancy
Despite the advances in cancer prevention, early detection, and treatments, all of which have led to improved cancer survival, globally, there is an increased incidence…
Urine test may detect aggressive prostate cancer, eliminate need for some biopsies
A home urine test demonstrated high sensitivity for detection of aggressive prostate cancer, according to study findings.The approach may help some men with lower risk…
Therapy for MYD88 L265P DLBCL
In this issue of Blood, Li et al report their finding that the small molecule compound lasalocid A specifically targets mutated MYD88 L265P protein in diff
